Glenmark launches SGLT2 Inhibitor Remogliflozin under brand names Remo, Remozen Meghna A Singhania30 April 2019 10:16 AM ISTGlenmark will commercialize Remogliflozin in India under the brand names 'Remo' and 'Remozen'.Mumbai: In a major relief to diabetics, Glenmark...
Diabetes Treatment: CDSCO expert panel marketing authorization Nod to Glenmark's SGLT2 Inhibitor Remogliflozin etabonate Meghna A Singhania31 March 2019 1:39 PM ISTNew Delhi: Mumbai-based Glenmark Pharmaceuticals Limited recently received the permission from the IND Committee of the Central Drugs Standard...